Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Capital Expenditures (2023 - 2025)

Immunome's Capital Expenditures history spans 3 years, with the latest figure at -$242000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 110.68% year-over-year to -$242000.0; the TTM value through Dec 2025 reached $1.0 million, down 64.15%, while the annual FY2025 figure was $1.0 million, 64.15% down from the prior year.
  • Capital Expenditures reached -$242000.0 in Q4 2025 per IMNM's latest filing, down from -$39000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.3 million in Q4 2024 to a low of -$928000.0 in Q2 2024.
  • Average Capital Expenditures over 3 years is $348666.7, with a median of $135500.0 recorded in 2023.
  • The largest YoY upside for Capital Expenditures was 2159.09% in 2024 against a maximum downside of 662.42% in 2024.
  • A 3-year view of Capital Expenditures shows it stood at -$110000.0 in 2023, then skyrocketed by 2159.09% to $2.3 million in 2024, then crashed by 110.68% to -$242000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Capital Expenditures are -$242000.0 (Q4 2025), -$39000.0 (Q3 2025), and $695000.0 (Q2 2025).